FDA Proposes Bundling Customized Gene-Editing Versions in One License Application Amid Limited Treatments for Rare Diseases

Key Facts

In October 2026, the U.S. Food and Drug Administration issued draft guidance proposing that multiple customized versions of a human genome-editing product be submitted in a single biologics license application. The document covers, according to the FDA, the application process and product management after approval, allowing versions targeting different genetic variants to be handled through one filing. The proposal is limited to treatments or preventive measures for monogenic diseases caused by known pathogenic variants. It also requires that the included versions be designed to achieve one gene-editing outcome. The move comes in a field where approved treatments are available for only about 5% of recognized rare diseases as of 2025, according to the FDA’s rare disease framework.

The draft clarifies that the proposal does not mean any new gene-editing modification would automatically be accepted, but instead establishes a framework for determining how much variation between versions is acceptable. For this purpose, the FDA introduces the concept of an “individual attribute space,” which defines the boundaries for varying attributes in genome-editing components. Inclusion of each version is tied to safety and activity criteria supported by data, according to the document. The proposed pathway would thus address differences between versions within documented limits, while requiring the editing to retain the same therapeutic outcome. The draft guidance also covers laboratory evaluation of safety and effectiveness, validation of manufacturing processes, labeling and indication information, and product naming and identification.

After approval, the FDA proposes allowing a new customized version to be added to an existing application if it falls within the defined attribute-space limits and tests demonstrate adequate safety and activity. The U.S. Department of Health and Human Services said this could allow the version to be added without additional clinical trials. According to the department’s statement, laboratory data specific to the new version could be used alongside data from the studies that supported the original approval. This means each new version would not necessarily need a separate clinical pathway, provided it meets the proposed technical and regulatory requirements. The mechanism remains part of nonbinding draft guidance and is not a final approval or a guarantee that any version will be added.

Individualized treatments target genetic differences that may vary from one patient to another; HHS says the treatment is designed to target the patient’s specific genetic variant. On February 23, 2026, the FDA had issued an earlier draft framework for individualized treatments for ultra-rare diseases, addressing how to generate safety and effectiveness evidence when small patient populations make randomized trials impractical. The agency said at the time that a gene-editing product targeting different mutations in the same gene could be included in one application, and that it could be evaluated through a master protocol. The earlier framework is linked to identifying the disease-causing defect and showing that the treatment targets the cause of the disease or a closely related biological pathway. The current October draft addresses submission of the license application and management of versions afterward, while the FDA said it intends to issue subsequent guidance on the design and conduct of clinical studies.

The FDA opened the draft for public comment and set November 27, 2026, as the deadline for submissions. The agency also invited the public to a meeting on its rare disease framework initiative on October 28, 2026, from 1 to 5 p.m. Eastern Time, to gather input that will guide its next steps. In a separate effort related to treatment access, HHS said the Centers for Medicare & Medicaid Services will issue a request for applications from manufacturers in the coming months. The request aims to expand a model for access to cell and gene therapies to include conditions beyond sickle cell disease. Details of the proposed pathway for individualized treatments remain subject to the comments the FDA receives and the subsequent guidance it intends to issue.